ReviewOncology reports2026
Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-inflammatory indices as predictors of pathologic complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review and meta-analysis of observational studies.World journal of surgical oncology · 2026Pooled it
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Advances in the mechanisms of extracellular vesicles and circulating tumor cells in hepatocellular carcinoma metastasis (Review).Molecular medicine reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets, while essential for hemostasis, have been recognized as critical mediators in cancer metastasis. The crosstalk between platelets and circulating tumor cells (CTCs) constitutes a key driver of metastasis, emerging as a focal point in oncology research. Elucidating the underlying mechanisms provides novel insights into tumor dissemination. The present review systematically traces the evolution of platelet‑CTC crosstalk, from receptor‑mediated adhesion to bidirectional molecular exchange, and its implications for metastatic progression. Additionally, the diagnostic significance of platelet‑CTC complexes as potential biomarkers for cancer detection and prognosis is highlighted. Finally, promising therapeutic strategies targeting the platelet‑CTC crosstalk are discussed. By integrating current knowledge, it was demonstrated that targeting platelet‑CTC crosstalk holds potential for improving cancer diagnosis and therapy, while also identifying avenues for future translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.